“A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants”
The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.
Drug - JNJ-26366821
Participants will receive sterile solution of JNJ-26366821 subcutaneously (SC).
Drug - Placebo
Participants will receive sodium chloride injection as placebo on Day 1.
A Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Volunteers